Poirot S S, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D
Institut National de la Santé et de la Recherche Médicale, Centre Hospitalier Universitaire de Rangueil, Toulouse, France.
Mol Pharmacol. 1994 Apr;45(4):599-607.
During the past few years, several antagonist ligands for cholecystokinin (CCK) receptors have been discovered, but the mechanism of action of these candidate drugs, as well as the nature of their molecular targets, remains poorly documented. In a previous study, we developed a new antagonist radioligand, 125I-Bolton-Hunter-labeled JMV-179, for the CCK-A receptor (CCK-AR), to analyze CCK antagonist binding sites in pancreatic plasma membranes. We found that 125I-Bolton-Hunter-labeled JMV-179 identified 4 times as many sites as did an agonist radioligand, although agonists were able to interact competitively with the entire population of antagonist sites. In the present work, using biochemical approaches we have identified and characterized CCK antagonist binding sites in pancreatic plasma membranes. We synthesized the photoactivable antagonist probe 125I-azidosalicyclic acid (ASA)-JMV-179. The binding of 125I-ASA-JMV-179 to plasma membranes was inhibited by JMV-179 (IC50, 6 +/- 2 nM), by (Thr28, Ahx31)-CCK-25-33 (IC50, 1.2 +/- 0.5 nM), and by the nonpeptide CCK-AR antagonist L-364,718 (IC50, 2 +/- 1 nM). Photoaffinity labeling using pancreatic membranes or acini demonstrated that 125I-ASA-JMV-179 detected a new 47-50-kDa protein in addition to the 85-100-kDa CCK-AR. The 47-50-kDa protein was not directly detected by a photoactivable agonist, but agonists could inhibit its covalent labeling by 125I-ASA-JMV-179 (IC50 for (Thr28,Ahx31)-CCK-25-33, 15 nM). In competition assays using nonsolubilized or solubilized membranes, this protein displayed binding features of the CCK-AR and was retained on immobilized wheat germ agglutinin, as was the CCK-AR. To further characterize the 47-50-kDa protein, deglycosylation and protease digestions were performed, and the digestion products were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Protease digestions of both the CCK-AR and the 47-50-kDa protein yielded identical labeled fragments, demonstrating a structural relationship between the two proteins. The CCK-AR, which has three potential sites for N-glycosylation on the amino-terminal extracellular domain and one on the second extracytoplasmic loop, was deglycosylated to a 42-kDa peptide. The 47-50-kDa protein was deglycosylated to a 35-kDa peptide. These data, and the localization of the labeled fragments in the amino acid sequence of the receptor, suggest that the 47-50-kDa protein represents a CCK-AR lacking its amino-terminal extracellular domain.(ABSTRACT TRUNCATED AT 400 WORDS)
在过去几年中,已发现几种胆囊收缩素(CCK)受体的拮抗剂配体,但这些候选药物的作用机制及其分子靶点的性质仍记录不足。在先前的一项研究中,我们开发了一种用于CCK-A受体(CCK-AR)的新型拮抗剂放射性配体,即125I-博尔顿-亨特标记的JMV-179,以分析胰腺质膜中的CCK拮抗剂结合位点。我们发现,125I-博尔顿-亨特标记的JMV-179识别出的位点数量是激动剂放射性配体的4倍,尽管激动剂能够与全部拮抗剂位点竞争性相互作用。在本研究中,我们使用生化方法鉴定并表征了胰腺质膜中的CCK拮抗剂结合位点。我们合成了可光活化的拮抗剂探针125I-叠氮水杨酸(ASA)-JMV-179。JMV-179(IC50,6±2 nM)、(Thr28,Ahx31)-CCK-25-33(IC50,1.2±0.5 nM)和非肽CCK-AR拮抗剂L-364,718(IC50,2±1 nM)均可抑制125I-ASA-JMV-179与质膜的结合。使用胰腺膜或腺泡进行的光亲和标记表明,125I-ASA-JMV-179除了检测到85-100 kDa的CCK-AR外,还检测到一种新的47-50 kDa蛋白。可光活化激动剂未直接检测到47-50 kDa蛋白,但激动剂可抑制其被125I-ASA-JMV-179共价标记((Thr28,Ahx31)-CCK-25-33的IC50为15 nM)。在使用未溶解或溶解膜的竞争试验中,该蛋白表现出CCK-AR的结合特征,并与CCK-AR一样保留在固定化麦胚凝集素上。为了进一步表征47-50 kDa蛋白,进行了去糖基化和蛋白酶消化,并通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳分离消化产物。CCK-AR和47-50 kDa蛋白的蛋白酶消化产生了相同的标记片段,表明这两种蛋白之间存在结构关系。CCK-AR在氨基末端细胞外结构域有三个潜在的N-糖基化位点,在第二个胞外环有一个,去糖基化后形成一个42 kDa的肽段。47-50 kDa蛋白去糖基化后形成一个35 kDa的肽段。这些数据以及标记片段在受体氨基酸序列中的定位表明,47-50 kDa蛋白代表一种缺少其氨基末端细胞外结构域的CCK-AR。(摘要截短至四百字)